<DOC>
	<DOC>NCT02126904</DOC>
	<brief_summary>The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.</brief_summary>
	<brief_title>Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept. patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>